Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world

How we helped our client maximise uptake and fine-tune the marketing strategy for their vaccine product in China

How we helped our client maximise uptake and fine-tune the marketing strategy for their vaccine product in China

Our client’s vaccine to protect against a condition prevalent in older adults had recently launched and secondary research was required to enable them to understand more about their target healthcare consumer and attitudes to health, well-being and vaccination. They needed to build a complete picture of how consumers are influenced, such as whether they are more influenced by HCP advice or online forums and social media. Furthermore they needed to develop an understanding for other out-of-pocket (OOP) competitor vaccines and what the future healthcare initiatives mean for vaccination in general.
 

read more »

How we helped determine the next groundbreaking development in a hard-to-treat respiratory disease

How we helped determine the next groundbreaking development in a hard-to-treat respiratory disease

Our client wanted to understand the current management in a complex therapy area, as treatment regimens require a combination of multiple drugs. Furthermore, the disease is most prevalent in emerging, hard-to-access markets. Understanding of drugs and treatment regimen preferences were required to help gauge likely success of the client’s new formulation in development, which would be part of a new regimen paradigm. As well as understanding current preferences and reactions to the new drug and regimen, the research needed to test several potential outcomes for the new formulation and assess performance against future new regimens likely to be available at the time of launch.

read more »

  • Posted by Rachel Howard
  • February 12, 2020
  • Articles

Beyond BRIC, Into MIST: Setting sights on pharma’s next-tier terrain

Beyond BRIC, Into MIST: Setting sights on pharma’s next-tier terrain

Emerging markets Director Rachel Howard was recently interviewed by Julian Upton from Pharmaceutical Executive about the BRIC and MIST pharma markets, and what to look out for over the next few years.

Although the BRIC countries (Brazil, Russia, India, China) or BRICS (if we add South Africa) tend to dominate discussions of “emerging” pharma markets, it is useful to cast an eye over “MIST,” another catchy acronym coined by economist Jim O’Neill that comprises Mexico, Indonesia, South Korea, and Turkey. In terms of their pharma markets, Attieh and Tannoury noted in 2017 that sales in both BRICS and MIST countries had doubled in five years, reaching a market share of approximately 20%, while McKinsey & Company, choosing to group Mexico and Turkey with BRIC, observed that these “BRICMT countries” would be instrumental in driving an expected USD$190 billion of pharma sales growth between 2015 and 2020. Given the volatile political and economic factors affecting some emerging market countries, however, the question of whether BRIC or MIST remain useful as pharma-market groupings is worth considering as we move into 2020 and beyond.

read more »

How we used WhatsApp and projective exercises to capture deep emotional insights into people living with HIV in South Africa

How we used WhatsApp and projective exercises to capture deep emotional insights into people living with HIV in South Africa

Our client wanted to identify and profile different segments of people living with HIV in order to understand key barriers and leverage points and ensure future engagement with their pharmaceutical portfolio. To achieve this, we needed to conduct an in-depth exploration of attitudes and behaviours of people living with HIV. However, stigma surrounding HIV in South Africa meant that respondents may have been unwilling to participate in a traditional interview. Even if they did, it was felt unlikely they would be open to direct questioning. We needed a different approach if we wanted to build a complete picture of life with HIV for our client.

read more »

  • Posted by Rachel Howard
  • January 16, 2020
  • Articles

Spotlight on Mexico: Healthcare under AMLO – One year on

Spotlight on Mexico: Healthcare under AMLO – One year on

Andrés Manuel López Obrador (commonly referred to by his initials AMLO) was elected President of Mexico in a landslide victory of December 2018. As we near the end of the first year of his six year term, we caught up with local expert Dr Xavier Tello, CEO of Strategic Consulting, to make sense of the latest changes in the healthcare system and consider what they mean for pharmaceutical manufacturers wishing to enter the Mexican market.“It has been a wild ride under AMLO”, Dr Tello told us. The changes have been rapid, complicated and unpredictable, and here we attempt to deconstruct the major events of the last 12 months.

read more »